Under the deal Cosmo will market the discovery and preclinical development services of NexMed’s BioQuant subsidiary to innovative pharmaceutical firms in the country.
NexMed CEO Bassam Damaj said that: “With the third largest concentration of biotechnology and pharmaceutical companies in the world behind the US and Europe, Japan represents a key growth opportunity.”
He explained that the agreement gives the contract research organisation (CRO) a solid presence in Japan, building on the links the firm has already established with drugmakers that operate in the country.